[1] Larkin J, Chiarion-Sileni V, Gonzalez R et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med 2019 Oct 17;381(16):1535-1546
[2] Robert C, Grob JJ, Stroyakovskiy D et al. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. N Engl J Med 2019 Aug 15;381(7):626-636
[3] Ascierto PA, Mandala M, Ferrucci PF et al. LBA45 - First report of efficacy and safety from the phase II study SECOMBIT (SEquential COMBo Immuno and Targeted therapy study). Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325
[4] Dummer R, Hauschild A, Santinami M et al. Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med 2020 Sep 17;383(12):1139-1148
[5] Ascierto PA, Del Vecchio M, Mandalá M et al. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncol 2020 Nov;21(11):1465-1477
[6] Menzies AM, Amaria RN, Rozeman EA et al. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat Med 2021 Feb;27(2):301-309
